The integral role of clinical research in clinical care

New England Journal of Medicine

Volumn 348, Issue 14, 2003, Pages 1386-1388

  Grunberg, Steven M ^a   Cefalu, William T ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL RESEARCH; EVIDENCE BASED MEDICINE; FINANCIAL MANAGEMENT; MEDICAL ETHICS; MORBIDITY; MORTALITY; PATIENT CARE; PHYSICIAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZATION; RESPONSIBILITY; SHORT SURVEY;

BIOMEDICAL AND BEHAVIORAL RESEARCH;

CLINICAL TRIALS; ETHICS, CLINICAL; ETHICS, RESEARCH; HUMANS; THERAPEUTICS;

EID: 0037417232     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMsb025342     Document Type: Short Survey

References (18)

1. Miiler FG, Rosenstein DL. The therapeutic orientation to clinical trials. N Engl J Med 2003;348:1383-6.
2. Schafer A. The ethics of the randomized clinical trial. N Engl J Med 1982;307:719-24.
3. Freedman B. Equipoise and the ethics of clinical research. N Engl J Med 1987;317:141-5.
4. Passamani E. Clinical trials - are they ethical? N Engl J Med 1991;324:1589-92.
5. Marquis D. How to resolve an ethical dilemma concerning randomized clinical trials. N Engl J Med 1999;341:691-3.
6. Emanuel EJ, Miller FG. The ethics of placebo-controlled trials - a middle ground. N Engl J Med 2001;345:915-9.
7. Steinbrook R. Protecting research subjects - the crisis at Johns Hopkins. N Engl J Med 2002;346:716-20. [Erratum, N Engl J Med 2002;346:1678.]
8. Lemonick MD, Goldstein A. At your own risk. Time. April 22, 2002:46-56.
9. Benson AB III, Pregler JP, Bean JA, Rademaker AW, Eshler B, Anderson K. Oncologists' reluctance to accrue patients onto clinical trials: an Illinois Cancer Center study. J Clin Oncol 1991;9:2067-75.
10. Antman KH. Overview of the six available randomized trials of high-dose chemotherapy with blood or marrow transplant in breast cancer. In: The National Institutes of Health Consensus Development Conference: adjuvant therapy for breast cancer. Journal of the National Cancer Institute monographs. No. 30. Bethesda, Md.: National Cancer Institute, 2001:114-6.
11. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
12. Du XL, Key CR, Osborne C, Mahnken JD, Goodwin JS. Discrepancy between consensus recommendations and actual community use of adjuvant chemotherapy in women with breast cancer. Ann Intern Med 2003;138:90-7.
13. Saaddine JB, Engelgau MM, Beckles GL, Gregg EW, Thompson TJ, Narayan KM. A diabetes report card for the United States: quality of care in the 1990s. Ann Intern Med 2002;136:565-74.
14. States that require health plans to cover patient care costs in clinical trials. Bethesda, Md.: National Cancer Institute, 2002. (Accessed March 4, 2003, at http://www.cancer.gov/clinicaltrials/developments/laws-about-clinical-trial- costs.)
15. Drazen JM, Koski G. To protect those who serve. N Engl J Med 2000;343:1643-5.
16. Ingelfinger FJ. The randomized clinical trial. N Engl J Med 1972; 287:100-1.
17. Tishler CL, Bartholomae S. The recruitment of normal healthy volunteers: a review of the literature on the use of financial incentives. J Clin Pharmacol 2002;42:363-73.
18. Kodish E, Post SG. Oncology and hope. J Clin Oncol 1995;13: 1817-22.